392 Federal Register / Vol. 70, No.
2 / Tuesday, January 4, 2005 / Notices
the basic class of controlled substance
listed.
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–61 Filed 1–3–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated July 23, 2004, and
published in the Federal Register on
August 10, 2004, (69 FR 48523), JFC
Technologies, LLC, 100 West Main
Street, Bound Brook, New Jersey 08805,
made application by letter to the Drug
Enforcement Administration (DEA) for
registration as a bulk manufacturer of
Diphenozylate (9170), a basic class of
controlled substance listed in Schedule
II.
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of JFC
Technologies, LLC to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated JFC Technologies, LLC to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–64 Filed 1–3–05; 8:45 am]
BILLING CODE 4410–09–P
VerDate jul<14>2003 18:02 Jan 03, 2005 Jkt 205001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated July 8, 2004, and
published in the Federal Register on
July 20, 2004, (69 FR 43436), Johnson
Matthey Inc., Custom Pharmaceuticals
Department, 2003 Nolte Drive, West
Deptford, New Jersey 08066, made
application by letter to the Drug
Enforcement Administration (DEA) for
registration as a bulk manufacturer of
Dihydromorphine (9145), a basic class
of controlled substance in Schedule I.
The company plans to manufacture
Dihydromorphine for internal use in
production of other controlled
substances for distribution to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc. to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Johnson Matthey Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–63 Filed 1–3–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to 21 CFR 1301.33(a), title
21 of the Code of Federal Regulations
(CFR), this is notice that on October 4,
2004, Noramco Inc., 1440 Olympic
Drive, Athens, Georgia 30601, made
application by letter to the Drug
Enforcement Administration (DEA) for
registration as a bulk manufacturer of
PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 E:\FR\FM\04JAN1.SGM
Dihydrocodeine (9120), a basic class of
controlled substance listed in Schedule
II.
The company plans to manufacture
the listed controlled substance in bulk
for distribution to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration, United
States Department of Justice,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Office
of Liaison and Policy (ODLR) and must
be filed no later than (60 days from
publication).
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–52 Filed 1–3–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to 21 CFR 1301.33(a), Title
21 of the Code of Federal Regulations
(CFR), this is notice that on October 4,
2004, Noramco Inc., Division of Ortho-
McNeil, Inc., 500 Old Swedes Landing
Road, Wilmington, Delaware 19801,
made application by renewal and by
letter to the Drug Enforcement
Administration (DEA) for registration as
a bulk manufacturer of Dihydrocodeine
(9120), a basic class of controlled
substance listed in Schedule II.
The company plans to manufacture
the listed controlled substance in bulk
for distribution to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration, United
States Department of Justice,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Office
04JAN1